Global respiratory and regenerative products company, AVITA Medical, has made an announcement informing that it has received the first commercial sales order for its the RECELL® Autologous Cell Harvesting Device, or RECELL® System, from U.S. burn centers. The company has also started shipping the product, it confirmed.
According to reports, on 20 September 2018, the U.S. Food and Drug Administration (FDA) approved the RECELL System used in treating severe thermal burns for patients aged 18 years or above. Apparently, 24 out of the 134 burns centers in the U.S. have already experienced using the RECELL® System and estimates show these 24 treat more than 30 percent of U.S. burn patients every year.
Chief Commercial Officer, Erin Liberto, stated that the FDA approval before the company’s U.S. market launch helped it to fulfill multiple orders for the RECELL System in a short span of time. Liberto said the company’s primary commercial focus is to recruit and train its U.S. field force, though many large burn centers already have notable experience in using the system through its Compassionate Use and Continued Access Programs as well as clinical trials.
The company had witnessed the desire of some burn centers to adopt its product before the national market launch. Some larger burn centers are also accelerating the adoption process and starting to integrate the RECELL System into their practice, Liberto added.
Using a small quantity of patient’s own skin for preparing Spray-On Skin Cells in less than 30 mins, the RECELL System reduces the donor skin requirements and delivers major clinical benefits to patients, while lowering the cost of treatment significantly. It can prepare substantial amount of suspension for treating a wound up to 80 times bigger than the donor skin sample size. A skin sample the size of a credit card, for instance, could be used in treating a wound covering the entire back of a patient.
